PURPOSE: To determine the intravitreous levels of interleukin-18 (IL-18) and vascular endothelial growth factor (VEGF) in patients with proliferative diabetic retinopathy (PDR) and to ascertain their association with PDR activity. METHODS: Thirty eyes of 30 diabetic patients with PDR were divided into two groups (active PDR, n = 17; quiescent PDR, n = 13). Fifteen eyes of 15 non-diabetic patients (macular hole, n = 9; epiretinal membrane, n = 6) served as controls. All vitreous fluid samples were obtained during vitrectomy. IL-18 and VEGF were measured by enzyme-linked immunosorbent assay. Serum glycosylated hemoglobin as well as the basic demographic data was documented. RESULTS: Both IL-18 and VEGF levels were higher in patients with PDR than control (P < 0 .01 and P < 0 .01, respectively). Both IL-18 and VEGF in active PDR were higher than those in quiescent PDR (P = 0.048 and P = 0.03, respectively). A significant positive correlation (Spearman rank correlation coefficient (r s) = 0.502, P = 0.005) between IL-18 and VEGF was observed in all PDR patients but not in the control. The correlation between VEGF and IL-18 was even stronger in the subgroup of active PDR (r s = 0.684; P = 0.002), whereas no significant correlation was found in the subgroup of quiescent PDR (r s = 0.049; P = 0.873). CONCLUSIONS: Both intravitreous IL-18 and VEGF were elevated in patients with PDR, which were closely correlated in active PDR. IL-18 may contribute to retinal angiogenesis by acting together with or via VEGF, and become the potential therapeutic target for treatment of PDR.
PURPOSE: To determine the intravitreous levels of interleukin-18 (IL-18) and vascular endothelial growth factor (VEGF) in patients with proliferative diabetic retinopathy (PDR) and to ascertain their association with PDR activity. METHODS: Thirty eyes of 30 diabeticpatients with PDR were divided into two groups (active PDR, n = 17; quiescent PDR, n = 13). Fifteen eyes of 15 non-diabeticpatients (macular hole, n = 9; epiretinal membrane, n = 6) served as controls. All vitreous fluid samples were obtained during vitrectomy. IL-18 and VEGF were measured by enzyme-linked immunosorbent assay. Serum glycosylated hemoglobin as well as the basic demographic data was documented. RESULTS: Both IL-18 and VEGF levels were higher in patients with PDR than control (P < 0 .01 and P < 0 .01, respectively). Both IL-18 and VEGF in active PDR were higher than those in quiescent PDR (P = 0.048 and P = 0.03, respectively). A significant positive correlation (Spearman rank correlation coefficient (r s) = 0.502, P = 0.005) between IL-18 and VEGF was observed in all PDR patients but not in the control. The correlation between VEGF and IL-18 was even stronger in the subgroup of active PDR (r s = 0.684; P = 0.002), whereas no significant correlation was found in the subgroup of quiescent PDR (r s = 0.049; P = 0.873). CONCLUSIONS: Both intravitreous IL-18 and VEGF were elevated in patients with PDR, which were closely correlated in active PDR. IL-18 may contribute to retinal angiogenesis by acting together with or via VEGF, and become the potential therapeutic target for treatment of PDR.
Authors: M V van Hecke; J M Dekker; G Nijpels; A C Moll; R J Heine; L M Bouter; B C P Polak; C D A Stehouwer Journal: Diabetologia Date: 2005-05-26 Impact factor: 10.122
Authors: A M W Spijkerman; M-A Gall; L Tarnow; J W R Twisk; E Lauritzen; H Lund-Andersen; J Emeis; H-H Parving; C D A Stehouwer Journal: Diabet Med Date: 2007-06-25 Impact factor: 4.359
Authors: L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park Journal: N Engl J Med Date: 1994-12-01 Impact factor: 91.245
Authors: Esther J Kuiper; Frans A Van Nieuwenhoven; Marc D de Smet; Jan C van Meurs; Michael W Tanck; Noelynn Oliver; Ingeborg Klaassen; Cornelis J F Van Noorden; Roel Goldschmeding; Reinier O Schlingemann Journal: PLoS One Date: 2008-07-16 Impact factor: 3.240
Authors: Siva S R Iyer; Mollie K Lagrew; Stephanie M Tillit; Ramak Roohipourmoallai; Samuel Korntner Journal: Int J Mol Sci Date: 2021-07-01 Impact factor: 5.923